Tags

Type your tag names separated by a space and hit enter

Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
Arch Virol. 2009; 154(10):1641-8.AV

Abstract

A 12.4-kDa peptide, corresponding to the entire ORF3 protein of hepatitis E virus (HEV), derived from human HEV genotype 4 and expressed in Escherichia coli as a fusion protein with a 17.5-kDa fragment of interleukin (IL)-1beta at the N-terminus, was recognized by HEV-reactive sera. Eight monkeys were immunized with the purified peptide, and seven were used as non-immunized controls. All 15 monkeys were challenged with HEV genotype 1 or 4. All control animals developed infection and hepatitis, and all but one vaccinated monkey became infected. Nevertheless, the vaccine was effective in reducing the virus titer and shortening the duration of viremia and fecal shedding. Furthermore, the vaccine provided some protection against hepatitis (1 of 2 monkeys in the two-dose regimen and 4 of 6 in the three-dose regimen did not develop severe hepatitis) compared to the controls. These results suggest that immunization with the bacterially expressed peptide may partially prevent experimental hepatitis, and even infection, in primates, following intravenous challenge with high doses of two HEV genotypes.

Authors+Show Affiliations

Department of Cell Biology, National Institute for the Control of Pharmaceutical and Biological Products, No. 2 Tiantanxili, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19763777

Citation

Ma, Hongxia, et al. "Immunogenicity and Efficacy of a Bacterially Expressed HEV ORF3 Peptide, Assessed By Experimental Infection of Primates." Archives of Virology, vol. 154, no. 10, 2009, pp. 1641-8.
Ma H, Song X, Harrison TJ, et al. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates. Arch Virol. 2009;154(10):1641-8.
Ma, H., Song, X., Harrison, T. J., Li, R., Huang, G., Zhang, H., Kong, W., & Wang, Y. (2009). Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates. Archives of Virology, 154(10), 1641-8. https://doi.org/10.1007/s00705-009-0496-4
Ma H, et al. Immunogenicity and Efficacy of a Bacterially Expressed HEV ORF3 Peptide, Assessed By Experimental Infection of Primates. Arch Virol. 2009;154(10):1641-8. PubMed PMID: 19763777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates. AU - Ma,Hongxia, AU - Song,Xiaoguo, AU - Harrison,Tim J, AU - Li,Rongcheng, AU - Huang,Guoyong, AU - Zhang,Heqiu, AU - Kong,Wei, AU - Wang,Youchun, Y1 - 2009/09/15/ PY - 2009/06/06/received PY - 2009/07/30/accepted PY - 2009/9/19/entrez PY - 2009/9/19/pubmed PY - 2010/2/20/medline SP - 1641 EP - 8 JF - Archives of virology JO - Arch Virol VL - 154 IS - 10 N2 - A 12.4-kDa peptide, corresponding to the entire ORF3 protein of hepatitis E virus (HEV), derived from human HEV genotype 4 and expressed in Escherichia coli as a fusion protein with a 17.5-kDa fragment of interleukin (IL)-1beta at the N-terminus, was recognized by HEV-reactive sera. Eight monkeys were immunized with the purified peptide, and seven were used as non-immunized controls. All 15 monkeys were challenged with HEV genotype 1 or 4. All control animals developed infection and hepatitis, and all but one vaccinated monkey became infected. Nevertheless, the vaccine was effective in reducing the virus titer and shortening the duration of viremia and fecal shedding. Furthermore, the vaccine provided some protection against hepatitis (1 of 2 monkeys in the two-dose regimen and 4 of 6 in the three-dose regimen did not develop severe hepatitis) compared to the controls. These results suggest that immunization with the bacterially expressed peptide may partially prevent experimental hepatitis, and even infection, in primates, following intravenous challenge with high doses of two HEV genotypes. SN - 1432-8798 UR - https://www.unboundmedicine.com/medline/citation/19763777/Immunogenicity_and_efficacy_of_a_bacterially_expressed_HEV_ORF3_peptide_assessed_by_experimental_infection_of_primates_ L2 - https://dx.doi.org/10.1007/s00705-009-0496-4 DB - PRIME DP - Unbound Medicine ER -